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1808Double Haploidentical Hematopoietic Stem Cell
Transplantation Results in Successful Engraftment
of Bone Marrow from Both Donors without
Graft-versus-Host or Graft-versus-Graft Effects
Chandra S. Biswas, Christopher T. Sauter, Cavan P. Bailey, Daniel Rittenberg, Xiaoling Luo,
Michelle M. Panis, Tulin Budak-Alpdogan, Dolores Grosso, Neal Flomenberg, Onder AlpdoganWe established double-haploidentical (DH) hematopoietic stem cell transplantation (HSCT) murine
models to explore competitive engraftment, graft-versus-graft effect and graft-versus-host disease
(GVHD). T cell–depleted (TCD) bone marrow (BM) cells from B6SJF1 (donor 1 [D1]) and B6D2F1 (donor
2 [D2]) mice achieved .90% donor engraftment when transplanted into B6CBAF1 mice. B6CBAF1 recip-
ients survived without evidence of GVHD when undergoing HSCT with TCD-BM from 2 haploidentical
donors, D1 and D2. DH-HSCTrecipients had significantly higher leukocyte and neutrophil counts than sin-
gle-haploidentical HSCT recipients from either D1 or D2. DH recipients consistently showed successful
mixed chimerism in both BM and spleen. Two other DH-HSCT models, B6D2F1 1 C3D2F1/B6C3F1
and B6CBAF1 1 B6SJLF1/B6D2F1, showed similar engraftment patterns. Low-dose T cell infusion
from both D1 and D2 increased the degree of early engraftment of the respective donors in BM and spleen;
however, this early engraftment pattern did not determine long-term engraftment dominance. In the long
term, minimally engrafted D1 BM recovered and comprised .50% of all donor- derived B, T, and natural
killer cells. We conclude that early BM engraftment is determined by donor T cell immunodominance, but
long-term engraftment is related to the engraftment potential of stem cells after DH-HSCT.
Biol Blood Marrow Transplant 18: 1808-1818 (2012)  2012 Published by Elsevier Inc. on behalf of American Society for
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Models, Immune reconstitutionINTRODUCTION
Initially, allogeneic hematopoietic stem cell
transplantation (HSCT) was limited to patients with
an HLA-identical related donor. To provide options
for patients lacking a matched related donor, regis-
tries of unrelated donors and cord blood banks have
been established as alternative matched stem cell
sources. The use of haploidentical (HI) donors
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oi.org/10.1016/j.bbmt.2012.09.012HI-HSCT has traditionally been associated with
higher mortality rates compared with transplantation
from well-matched donors, which has limited its
application. HI-HSCT has produced impressive
results in transplant recipients in complete remission
in selected centers [1-4]. Rigorously T cell–depleted
(TCD) HI grafts avoid severe graft-versus host dis-
ease (GVHD) and increase the safety profile of
HI-HSCT. T cell depletion techniques have been
successful in decreasing GVHD, but have been asso-
ciated with higher rates of relapse, graft rejection, and
opportunistic infection owing to a lack of T cells in
the donor inoculum [1,5]. Outstanding clinical
results have been achieved with large doses of
CD34-selected hematopoietic stem cells [5]. Unfor-
tunately, the success rate of HI-HSCT remains low
in patients with resistant leukemia, suggesting that
leukemic cells are able to escape the donor immune
system’s graft-versus-tumor (GVT) effects.
MHCmolecules play a critical role in immune rec-
ognition and response. A decrease in MHC antigen
Biol Blood Marrow Transplant 18:1808-1818, 2012 1809Double Haploidentical Transplantexpression is an important contributor to the escape
from immune surveillance.
Recently, a striking example in patients with dis-
ease recurrence after HI-HSCTwas reported in which
the malignant clones lost the expression of disparate
HLA haplotype, the presumed dominant target after
HI-HSCT. Vago et al. [6] evaluated 43 patients who
underwent HI-HSCT for acute leukemia or myelo-
dysplastic syndrome and found that 5 of 17 patients
with leukemia relapse had mutant leukemic cells that
lost mismatched MHC haplotype expression with ac-
quired uniparental disomy. T cells targeting an un-
shared haplotype were impaired, which allowed
expansion of the resistant clones and eventually caused
clinical relapse [6]. A Japanese group also reported
similar cases with uniparental disomy and leukemia
relapse after HI-HSCT [7].
Immunologic escape occurs through other mech-
anisms as well, but loss of target MHC antigens is an
important mechanism that could provide a target for
the development of novel treatment options. The use
of 2 HI donors, each ideally targeting the opposite
host MHC haplotype, could maximize the number
of target antigens that can be seen by donor-derived
GVT effector cells. In this scenario, the loss of one
MHC haplotype (or other target antigens) would
not cripple the GVT response. Colvin et al. [8]
found that HI donor lymphocyte infusion after ad-
ministration of a minimal conditioning regimen
could produce remission, with all donor lymphocyte
infusion products rejected. This finding demon-
strates the potency of these cells in eradicating ma-
lignancy by targeting haplomismatched tumor cells
in even a short period. However, the use of 2 HI do-
nors might trigger other problems, including a graft-
versus-graft (GVG) effect, possibly leading to graft
failure or poor graft function. Tetraparental chime-
ric mouse models, in which TCD bone marrow
(BM) from both parental strains is transplanted
into the F1 strain, have produced stable long-term
chimerism [9].
Although each parent is normally alloreactive
toward the haplotype inherited from the opposite par-
ent, stable long-term chimerism and the coexistence of
lymphohematopoietic cells from both donors occur
through tolerance induction. Other methods can be
used to induce tolerance in allogeneic HSCT. Chester
et al. [10] administered BM from 2 allogeneic MHC-
mismatched donors together with TCD syngeneic
BM.When donor marrow was TCD, stable mixed chi-
merism from both donors was seen; however, when
donor T cells remained in the graft, 1 of the 2 donors
ultimately dominated [10].
Here we report for the first time that double HI
(DH) HSCT results in successful engraftment of BM
from both donors without GVH or GVG effects in
TCD models.MATERIALS AND METHODS
BM Transplantation
Female C57BL/6 (B6, H-2Kb), B6CBAF1 (H-
2Kb/k), B6SJL (H-2Kb/s), C3D2F1 (H2Kk/d), and
B6D2F1 (H2Kb/d) mice were obtained from Jackson
Laboratory (Bar Harbor, ME). Mice used in the BM
transplantation (BMT) experiments were between 10
and 12 weeks of age. The BMT protocols were
approved by the Institutional Animal Care and Use
Committee of Thomas Jefferson University.
BM cells were removed aseptically from femurs
and tibias and rendered TCD by incubation with
anti-Thy 1.2 antibody for 30 minutes at 4C, followed
by incubation with Low-TOX-M rabbit complement
(Cedarlane Laboratories, Hornby, ON, Canada) for
40 minutes at 37C or, alternatively, by anti-CD5
magnetic bead depletion (Miltenyi Biotech, Auburn,
CA). Typical levels of contaminating T cells after
complement depletion ranged from 0.2% to 0.5% of
all BM leukocytes.
Splenic T cells were obtained by positive selection
with anti-CD5 antibodies conjugated tomagnetic beads
(Miltenyi Biotech). Cells (5  106 BM cells with or
without splenic T cells) were resuspended in DMEM
and transplanted by tail vein infusion (0.25mL total vol-
ume) into lethally irradiated recipients on day 0. In
some experiments, mice were challenged with P815
murine mastocytoma cells by tail vein infusion at the
time of transplantation. On day 0 pretransplantation,
recipients received 11-13 Gy of total body irradiation
(strain-dependent) from a 137Cs source in 2 split doses,
with a 3-hour interval between doses to reduce gastro-
intestinal toxicity. Mice were housed in sterilized
microisolator cages and received normal chow and
autoclaved hyperchlorinated drinking water (pH 3.0).
Reagents and Antibodies
Antimurine CD16/CD32 FcR block (2.4G2) and
all of the following fluorochrome- labeled antibodies
againstmurine antigenswere obtained fromBDBiosci-
ences (San Jose, CA): anti-H2Kd (SF1-1.1), anti-H2Kb
(AF6-88.5), anti-H2Kk (36-7-5), anti-H2Ks (KH49),
anti-CD45.1 (A20), anti-CD45R/B220 (RA3-6B2),
anti-NK1.1 (PK136), anti-CD3 (500A2), anti-CD4
(RM4-5), anti-CD8 (53-6.7), anti-Gr1 (RB6-8C5),
anti-CD11b (M1/70), anti-TNF-a (MP6-XT22),
anti-IFN-g (XMG1.2), allophycocyanin-streptavidin,
and isotype controls. Rat IgG2a-k (R35-95), hamster
IgG1-k (Ha4/8), phorbol 12-myristate 13-acetate
(PMA), ionomycin, brefeldin A, and concanavalin A
were obtained from Sigma-Aldrich (Allentown, PA).
Flow Cytometry Analysis
Cells were washed in FACS buffer (PBS with
0.5% BSA and 0.1% sodium azide), and 106 cells/mL
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CD32 FcR block. Cells were then incubated for an-
other 30 minutes at 4C with antibodies and washed
twice with FACS buffer. The stained cells were resus-
pended in FACS buffer and acquired on a FACSCali-
bur or LSR II flow cytometer with CellQuest or
FACSdiva software, respectively (BD Diagnostic Sys-
tems, Sparks, MD), and analyzed with Flowjo software
(TreeStar, San Carlos, CA).Intracellular Staining
Cytokine secretion was stimulated in isolated sple-
nocytes by incubation in PMA (10 ng/mL) and iono-
mycin (2 mM) for 5 hours. After a 2-hour stimulation
with PMA and ionomycin, 10 mg/mL brefeldin A was
added, After incubation for another 3 hours, cells
were collected and counted for intracellular staining.
Splenocytes were washed and stained with primary
(surface) fluorochrome-conjugated antibodies, fixed
and permeabilized with the BD Cytofix/Cytoperm
Kit (BD Biosciences), and then stained with intracellu-
lar antibodies (ie, TNF-a and IFN-g).Cytotoxicity with Cromium Release Assay
Target cells were labeled with 100 mCi 51Cr for
1 hour, and after 3 washes were plated in U-bottomed
Costar plates (Corning, Corning, NY) at a concentra-
tion of 104 cells/well. Splenic T cells were added at var-
ious effector-to-target ratios (ie, 40:1, 20:1, and 10:1) in
a final volume of 200 mL, followed by incubation for
4-6 hours at 37C and 5% CO2. Subsequently, 35 mL
of supernatant was removed from each well and
counted in a gamma counter (Walec 1450 Microbeta-
plus; PerkinElmer,Waltham,MA) to determine exper-
imental release. Spontaneous release was obtained
from wells that contained only target cells, and total
releasewas obtained fromwells treatedwith 5%Triton
X-100. The spontaneous release was\15% of the total
release. Percent cytotoxicity was calculated using
the following formula: percent cytotoxicity 5 100 
(experimental release 2 spontaneous release) / (total
release 2 spontaneous release).Assessment of GVHD
The severity of GVHDwas assessed with a clinical
GVHD scoring system as described by Cooke et al.
[11]. In brief, each week, ear-tagged animals in coded
cages were scored on a scale of 0-2 for 5 clinical param-
eters: weight loss, posture, activity, fur, and skin.
A clinical GVHD index was generated by summing
the 5 scores (total score, 0-10). Survival was monitored
daily. Animals with a score .5 were considered mori-
bund and were euthanized.Statistics
All values are expressed as mean 6 SEM. Statisti-
cal comparison of experimental data was performed
using the nonparametric unpaired Mann-Whitney
U test. A P value\.05 was considered statistically sig-
nificant. Log-rank analysis was used in the survival
analysis.RESULTS
SH BM Engrafted Well and Resulted in Better
Antitumor Activity
We generated our HI transplant models using
hybrid mice with a B6 background that shared the
same haplotype (H2Kb). Lethally irradiated
B6CBAF1 (H2Kb/k) recipients were transplanted
with TCD-BM cells from B6D2F1 (H2Kb/d) donors.
Recipients were euthanized at days 28, 42, and 84,
and showed .90% donor cell engraftment, including
donor-derived lymphopoiesis and myelopoiesis in the
spleen and BM (Figure 1A-D and data not shown),
with no evidence of GVHD. Interestingly, all natural
killer (NK) cells and B cells were from donor BM
even in the early period ofHSCT.Conversely, residual
host T cells constituted half of the T cell population at
day 28, but donor T cell engraftment eventually
reached 90% by day 84 posttransplantation.
All B6D2F1 recipients were challenged with
P815 murine mastocytoma (H2d) cells to compare
the graft-versus-leukemia effect of SH-HSCT and
the parent-FI HSCT model. In this model, low-
dose T cells from the donors were infused as well.
The SH TCD-BM and add-on T cells model dem-
onstrated better antileukemic activity than the
parent-FI HSCT model (Figure 2A). Ten days
after transplantation, splenocytes of the recipients
of either B6- or B6CBAF1-derived TCD-BM and
low-dose T cells were harvested and used in a 51Cr
release assay to determine eytotoxicity against
P815 cells. Compared with B6 splenocytes,
B6CBAF1 splenocytes exhibited statistically higher
cytotoxic activity against P815 tumor cells. None
of the donor cells showed cytotoxicity against
C1498 tumor cells, nonspecific control, expressing
H2Kb (Figure 2B) (data not shown).
Recipients of TCD-BM transplantation with
low-dose T cell infusion but without tumor
challenge were euthanized 28 days after transplanta-
tion. T cell numbers were slightly increased in
recipients of SH HSCT compared with recipients
of B6 splenocytes, whereas percentages of T cells
in the spleen were not statistically different in the
2 recipients (Figure 2C). CD81 T cell levels were
significantly higher in recipients of SH HSCT,
whereas intracellular IFN-g levels of T cells were
similar in the 2 groups (Figure 2D). Interestingly,
Figure 1. Haploidentical BM engrafted significantly with no signs of GVHD. Lethally irradiated (13 Gy) B6CBAF1 recipients underwent transplantation
with 5 106 TCD-BM cells from B6D2F1mice. Mice were euthanized at 4, 6, and 12 weeks after transplantation, and spleens were harvested. Single-cell
suspensions were obtained, and splenocytes were stained with anti-H2Kd, anti-CD3, anti-NK1.1, and anti-B220 antibodies. Cells were analyzed by flow
cytometry. Donor cells were determined by positive H2Kd expression on the cell surface. Each harvest contained 5 mice.
Biol Blood Marrow Transplant 18:1808-1818, 2012 1811Double Haploidentical TransplantTNF-a secretion of CD81 T cells was significantly
higher in recipients of B6CBAF1 splenocytes com-
pared with B6 recipients. We concluded that HI T
cells provide better antitumor activity in the
B6CBAF1/B6D2F1 model compared with the
parent/F1 model.DH HSCT Results in Successful Engraftment of
BM from Both Donors without GVG or GVHD
We compared 2 different SH transplant models
with 5  106 BM cells from either B6SJF1 mice
(H2Kb/s; SH1) or B6CBAF1 mice (H2Kb/k; SH2)
and a DH transplant model with an equal dose of
2.5  106 BM cells from both donors (Figure 3).
There was no early transplantation-related mortality
or graft failure, which might suggest GVG or host-
versus-graft (HVG) activity, in the recipients of
DH-HSCT. There were no significant differences
between the groups in terms of weight loss and
GVHD scores (Figure 3A and data not shown). All
mice gained weight by week 3. At day 90 posttrans-
plantation, peripheral blood samples revealed signifi-
cantly higher WBC and neutrophil counts in
DH-HSCT recipients compared with SH HSCT re-
cipients (Figure 3B and C). Platelet counts and Hb
levels were similar among the groups (Figure 3D
and E). DH-HSCT recipients consistently showed
successful mixed chimeric engraftment in both BMand spleen. More than 99% of BM cells and 98%
splenic cells were of donor origin (Figure 3F, G,
and J). Interestingly, there was no difference in donor
chimerism between DH and SH transplant recipi-
ents. Almost all B cells, myeloid cells, and NK
cells in the spleen and BM were of donor origin
(Figure 3I, K, and M and data not shown), and
DH-HSCT recipients had mixed chimerism. T cell
reconstitution patterns were similar in DH-HSCT
and SH-HSCT recipients were similar, and even at
90 days posttransplantation, approximately 10% re-
sidual host-derived T cells were detected in both
spleen and BM (Figure 3H and L).
To confirm that these finding were not strain-
specific, we examined the engraftment of DH-
HSCT in a different mouse model. In this model,
both donors were HI to one another with different
haplotypes than the host cells, which is clinically
relevant to any parent–child combination with HI-
matched sibling donors. Lethally irradiated
B6C3F1 recipients underwent transplantation with
TCD-BM cells from B6D2F1 and C3D2F1 donor
mice and were harvested at day 35 after transplanta-
tion. There were no differences in thymic, splenic
and BM cellularity posttransplantation (data not
shown). Spleen and BM showed .90% donor
engraftment from both donors (Figure 4A). Donor
1 (D1) was moderately dominant in the spleen
and BM. B cell and T cell reconstitution revealed
Figure 2. Recipients of HI SCT shows better antitumor effect than recipients of parent-F1 SCT. Lethally irradiated (13 Gy) B6D2F1 recipients under-
went transplantation with 5  106 TCD BM cells and 1  105 T cells from either B6 or B6CBAF1 mice. (A) All recipients also received 1  104 P815
murine mastocytoma cells on the day of transplantation. Mice were analyzed for survival at 100 days posttransplantation. Each group contained 10 mice.
Kaplan-Mayer curves are shown. Log-rank analysis was used for statistical analysis. (B) Lethally irradiated (13 Gy) B6D2F1 recipients underwent trans-
plantationwith 5 106 TCD-BM cells from either a B6 donor or a B6CBAF1. Single-cell suspensions were prepared from the spleens harvested from the
recipients at day 10 posttransplantation.With the 51Cr release assay, the cytotoxicity effect of the splenocytes (effector, E) on P815murinemastocytoma
cells (target, T) was measured at different E/T ratios, as indicated. Each group contained 5 mice. *P\.05. (C and D) B6D2F1 mice underwent trans-
plantation as described in (A). All mice were euthanized on day 28 posttransplantation. Spleens were harvested, and single-cell suspensions were pre-
pared. Splenocytes were stained with anti-H2Kd, anti-CD4, and anti-CD8, followed by intracellular cytokine staining done according to the
manufacturer’s protocol (BD Pharmingen, San Diego, CA). The cells were analyzed by multicolor flow cytometry. The total numbers of CD41 and
CD81 cells are shown in (C). The percentage of donor-derived IFN-g–and TNF-a–secreting CD81 T cells are shown in (D). The data are representative
of 2 independent experiments. Each group contained 5 mice. The Mann-Whitney U test was used for statistical analysis.
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shown in Figure 3 (Figure 4B-D). None of the
mice showed signs of GVHD or died in the early
posttransplantation period (data not shown). We
again concluded that TCD BM cells from two HI
donors could engraft well without GVG and
GVHD in HI recipients.
Low-Dose T Cell Infusion from Either D1 or D2
Increased the Degree of Dominance of That
Donor’s Cells in the Spleen and BM
Low-dose add-on T cell infusions from donors
were explored for safety and their effects on engraft-
ment patterns. In these experiments, all recipients re-
ceived the same amount of DH TCD parent-FI
HSCT model BM from B6SJLF1 (H2Kb/s) and
B6D2F1 (H2Kb/d) mice and were also infused with
total 1  105 T cells from one or both donor strains.
The control group did not receive any T cells. Mice
were harvested at day 30 after HSCT. Interestingly,
a low-dose T cell infusion did not result in any change
in thymopoiesis or BM cellularity but produced a milddecrease in splenic cellularity (data not shown). Donor
T cell infusion increased early engraftment of the
respective source donor in the spleen and BM and
decreased residual host T cells (Figure 5A and B).
These data show a similar pattern to the findings
reported by Chester et al. [10]. We concluded that
add-on T cells increase the same type of donor chime-
rism. This experiment also demonstrated that D2 cells
were dominant in the early engraftment period and
that infusion of both D1 and D2 T cells resulted
in .95% D2 cell engraftment, suggesting that D2 T
cells are immunologically more potent than D1 T
cells.
Early Engraftment Pattern in DH-HSCT
Recipients Does Not Predict Long-Term
Engraftment Pattern
Evaluation of mixed chimerism at varying time
points (days 30, 60, and 90) after DH-HSCT revealed
different engraftment dominance patterns. At 90 days
posttransplantation, D1 engraftment in the spleen
was increased from 17% to 51%, whereas D2
Figure 3. DH-HSCTrecipients engrafted well, with no GVHD or graft failure. Lethally irradiated (13 Gy) B6CBAF1 recipients underwent transplan-
tation with 5 106 TCD-BM cells from the B6SJLF1 donor (SH1), B6D2F1 donor (SH2), or both donors (DH). (A)Weight curve for the recipients over
90 days posttransplantation. (B-E) Blood was collected via retro orbital bleeding at day 90 from recipients after transplantation and analyzed for WBC
(B), neutrophils (NE) (C), hemoglobin (HB) (D), and platelets (PLT) (E). The cells from both HI donors engrafted well in the DH-HSCTrecipients. Mice
were euthanized at day 90, and spleens and BM cells were harvested. Cells were stained with anti-H2kD, anti-H2kk, anti-H2ks, anti-CD45.1, anti-CD3,
anti-B220, Gr-1, and anti-CD11b and analyzed by multicolor flow cytometry. Shown are percent engraftment of total spleen (F and G) and spleen T cells
(H), B cells (I), and myeloid cells, and total BM (J) and BM B cells (K), T cells (L), and myeloid cells (M). Each group contained 8 mice, and the experiment
was repeated twice. The nonparametric Mann-Whitney U test was used for statistical analysis. *P\.05.
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(Figure 6A). T cell chimerism exhibited more impres-
sive changes in relative engraftment. D1-derived T
cells composed only 7% of splenic T cells at day 30,
but expanded to 60% at day 90 (Figure 6B). Splenic
B cells and NK cells followed a similar chimerism pat-
tern, with the exception of residual host cells in the
early posttransplantation period (Figure 6C and D).
T cell, B cell, and myeloid cell chimerism in BM
showed similar patterns after DH-HSCT (data not
shown).
Infusion of Low-Dose HI T Cells Results in
Enhanced Antitumor Activity after
Transplantation
In this experiment, we challenged recipients of DH
TCD-BM with P815 tumor cells. B6D2F1 mice
underwent transplantation with TCD-BM and add-
on low-dose T cells from B6CBAF1, B6SJLF1, or
both. Interestingly, recipients of DH TCD-BM ex-
hibited significantly better survival compared with
recipients of SH TCD-BM (Figure 7A). Moreover,
after a low-dose T cell infusion (1  105), survivalwas significantly better in recipients of B6CBAF1
BM compared with recipients of B6SJLF1 BM. In con-
trast to the TCD model, survival was similar in recip-
ients of DHTCD-BMwith DHT cells and recipients
of B6CBAF1 BM with SH T cells (Figure 7B). These
data suggest that B6SJLF1 cells have less antitumor
activity than B6CBAF1 T cells (Figure 7C). T cells
from 2 different donors exhibited different antitumor
activity and possibly also antihost activity in DH-
HSCT recipients.
This leads to the question of whether or not
B6CBAF1 T cells are immunologically more potent
thanB6SJLF1 cells in terms of engraftment. Lethally ir-
radiated B6D2F1 mice underwent transplantation with
TCDB6CBAF1 andB6SJF1BMcells, and engraftment
in the spleen was evaluated. Although most of the early
engraftment consisted of B6CBAF1T cells, comparable
chimerism was observed at 100 days after transplanta-
tion (Figure 7D and E). When in vitro functions of
B6SJLF1 and B6CBAF1 compared with proliferation
kinetics, mitogen-induced T cell proliferation of
B6SJLF1 T cells were lower than proliferation of
B6CBAF1 T cells (data not shown).
Figure 4. DH-HSCT (B6D2F1 BM 1 C3D2F1 BM/B6C3F1) engrafted well in recipients of HSCT. Lethally irradiated (13 Gy) B6C3F1 (host) recip-
ients with TCD-BM cells from B6D2F1 (D1) and C3D2F1 (D2) mice, and spleens were harvested on day 35 posttransplantation. (A) In single cell sus-
pensions, cells were stained with anti-H2kd, -H2kk, -H2kb, -CD4, and -CD8 antibodies analyzed by multicolor flow cytometry. (B-D) Chimerism
patterns of donor-derived splenocytes (B) and splenic T cells (C), and B cells (D). Each group contained 10 mice.
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a change in intracellular cytokine levels after PMA-
ionomycin stimulation. B6D2F1 mice underwent
transplantation from B6CBAF1 and B6SJLF1 TCD-
BM cells with 1  105 T cells (1  105) from either
B6SJLF1 (D1) or B6CBAF1 (D2) mice. Recipient
mice were euthanized and spleens harvested at day
30 posttransplantation. Intracellular IFN-g levels of
donor-derived T cells were measured. There was no
difference in intracellular cytokine levels between
D1-derived T cells and D2-derived T cells (Table 1).
These data suggest that immunodominant T cells are
involved in early stem cell engraftment and lymphoid
reconstitution as well as in GVT activity, but do not
predict long-term engraftment.DISCUSSION
In this study, we have shown that DH TCD-BM
can engraft well without GVG, GVHD, or graft fail-
ure in 3 different donor–host combinations. To the
best of our knowledge, this is the first study of DH-
HSCT in clinically relevant models.
Our SHmurine models mimicked possible scenar-
ios that were more clinically relevant than traditional
parent/F1 and F1/parent models [12-14]. The
lack of host-versus-graft reaction in the parent/F1model and the presence of only 2 haplotypes in both
models urged us to develop new models.
More than 3 decades ago, von Boehmer et al. [9]
established that tetraparental BM chimeras were
produced by injecting lethally irradiated F1 hybrids
with relatively high doses of TCD-BM cells from
both allogeneic parental strains. The mice survived
in excellent health and showed approximately
50:50 (parent:parent) stable lymphoid cell chime-
rism persisting for at least several months after irra-
diation. Moreover, thymus, lymph node, and
thoracic duct lymphocytes demonstrated specific un-
responsiveness to host mixed leukocyte reaction de-
terminants, suggesting induction of a tolerant T cell
population.
An interesting study from the National Cancer In-
stitute demonstrated that 2 allogeneic TCD-BM cells
with syngeneic BM cells engrafted well by inducing
tolerance to skin grafts from both allogeneic donors
[10]. When animals were given non-TCD allogeneic
BM from 2 different donors in addition to TCD syn-
geneic BM, fully allogeneic chimeras were reconsti-
tuted in which one or the other allogeneic donor
prevailed. The investigators concluded that multiple
allogeneic donor BM cells can engraft simultaneously
in the mixed marrowmodel; in addition, multiple allo-
geneic engraftment confers transplantation tolerance
to multiple donors [10].
Figure 5. Single or double donor T cells increased the same type of
donor BM engraftment in recipients of DH-HSCT. Lethally irradiated
(13 Gy) B6CBAF1 recipients underwent transplantation with 5  106
TCD-BM cells from B6SJLF1 (D1), B6D2F1 (D2), or both donor mice
(DH). Recipients also received 1  105 T cells from either B6SJLF1
(T1) or B6D2F1 (T2) or both donor mice (DT) along with TCD-BM.
Mice were euthanized on day 28 posttransplantation. Spleens and BM
were harvested, and single cell suspensions were prepared from each
organ. These cells were then stained with anti-H2Kd, anti-H2kk, anti-
H2Ks, and anti-CD45.1. Cells were analyzed by multicolor flow cytom-
etry. The percent engraftment of total spleen (A) and BM (B) cells are
shown. Each group contained 8-10 mice. *P\.05.
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is essential for generating mixed chimeras originating
from both donors. We used TCD-HI BM in all our
HSCT experiments and in some experiments added
donor-derived T cells to induce graft-versus-leukemia
and GVH effects. Satake et al. [15] reported that recip-
ients of HI transplants had significantly higher antitu-
mor activity and less severe GVHD, correlated with
lower CXCR3 expression on donor T cells and higher
IFN-g expression on host NK cells. In contrast, in
the present study we did not find increased IFN-g
secretion in host-derived T cells or NK cells after
HI-HSCT, although we did detect better antitumor
activity both in vivo and in vitro in haplomatched do-
nor T cells compared with parent/F1 mismatched
donor cells.
Achievement of tolerance after HI-HSCT is
crucial for success and long-term stability of the trans-
plant. Posttransplantation administration of high-dose
cyclophosphamide can induce T cell tolerance and de-
crease the risk of GVHD by eliminating alloreactive T
cell clones [16]. The prevention of T cell activation via
blocking signal molecules also could induce toleranceafter HSCT. BM cells from 2 different donors
(BALB/c and CBA mice) engrafted with multilineage
double chimerism in MHC-mismatched recipients
and induced immunologic donor-specific tolerance
to skin allografts in the host after treatment with
anti-CD45RB and anti-CD154 monoclonal anti-
bodies [17]. We have found no clinical GVHD in
our TCD or T cell–replete models. We suggest that
our low T cell dose (approximately 1 log lower than
in other transplant models) is sufficient to induce
GVT activity without causing lethal GVHD.
To address the tolerance of newly generated T
cells in HI-HSCT recipients, we developed a toleriza-
tion transplantation model. Donor-derived T cells
were separated from HI-HSCT recipients and infused
at a higher dose (.1 log) to lethally irradiated mice of
an unshared haplotype strain. In our preliminary
experiments, we did not observe any signs of GVHD
in these mice (data not shown). We suggest that newly
generated de novo T cells arise from haplomatched
BM and become tolerant to the unshared haplotype
of the recipient after HI-HSCT.
Umbilical cord blood (UCB) is an important
example of the use of 2 different stem cell sources for
HSCT. Transplantation of 2 different UCB units,
often UCB units with bidirectional mismatches at 1
or 2MHC loci, has resulted in successful mixed chime-
ric engraftment, making this modality an acceptable
HSCT option for adult patients. Initial concerns
regarding the possibility of a cross-immunologic rejec-
tion (ie, GVG response) between 2 mismatched UCB
units were allayed with the demonstration of consis-
tent engraftment in practice [18]. In addition, double
UCB transplantations have been consistently associ-
ated with lower rates of GVHD [19] and relapse
[20,21] compared with single UCB transplantations.
A recent report demonstrated delayed immune recon-
stitution, specifically in regard to T cell recovery and
increased risk of infection after doubleUCB transplan-
tation [22]. We did not find delayed immune reconsti-
tution compared with SH-HSCT, and, interestingly,
we found better neutrophil recovery in DH-HSCT
recipients. In vitro T cell proliferation and cytokine
secretion of T cells were comparable in the DH-
HSCT recipients and SH-HSCT controls.
Engraftment dominance of UCB units and their
varying dominance patterns during the posttransplan-
tation period (ie, early versus late engraftment) have
been previously reported after double UCB transplan-
tation [23,24]. The mechanism of dominance is not
well understood, but higher CD341 cell content
[23], higher NK cell content, and being first in the
order of infusion [23,24] have all been associated
with dominance of one UCB unit over the other.
Two recent reports noted that early CD31 peripheral
blood chimerism predicts the long-term engraftment
outlook [25,26]. Taken together, these findings
Figure 6. Early engraftment pattern in DH-HSCT recipients does not predict the long-term engraftment pattern. Data from repeated DH-HSCT
experiments were compiled and compared for the analysis and prediction of donor (D1 and D2)-derived cellular engraftment pattern in the spleens
of host at early and late posttransplantation. Shown are chimerism patterns of spleen cells (A) and splenic T cells (B), B cells (C), and NK cells (D)
at days 30, 60, and 90 posttransplantation from DH-HSCTexperiments. The total number of mice studied on each day varied between 10 and 20.
1816 Biol Blood Marrow Transplant 18:1808-1818, 2012C. S. Biswas et al.suggest that cells from the donor that engrafts earlier
or in larger numbers may exert effector responses
against the cells of the other donor. This is supported
by the detection of evolving cord dominance as early as
the day of engraftment [27]. Despite the dominance ofFigure 7. DH-HSCT does not abrogate antitumor activity. (A) Lethally irradia
TCD-BM cells from B6SJLF1, B6CBAF1, or both donor mice. (B) Some mice re
B6D2F1 mice received BM from B6SJLF1 with a titrated T cell dose between
mastocytoma cells on the day of transplantation. Survival was assessed for 100 d
curves are shown. Log-rank analysis was used for statistical analysis. (D and E) C
on day 30 and day 100 posttransplantation, respectively, using similar method
recipients underwent transplantation with 5  106 TCD-BM cells from B6SJLhematopoietic cells of one donor over the other, the
use of 2 donor UCB units has been associated with de-
creased rates of relapse compared with single UCB
unit transplantation [20,21]. Liu et al. [28] reported
that the combination of unrelated UCB andted (13 Gy) B6D2F1 recipients underwent transplantation with 5  106
ceived 1 105 T cells from B6SJLF1, B6CBAF1, or both donor mice. (C)
1  105 and 1  106. All recipients also received 1  104 P815 murine
ays posttransplantation. Each group contained 10-20mice. Kaplan-Mayer
himerism patterns of splenocytes and splenic Tand B cells were analyzed
s as described in Figure 3. In brief, lethally irradiated (13 Gy) B6D2F1
F1 (SH1), B6CBAF1 (SH2), or both donor mice (DH).
Table 1. B6CBAF1- and B6SJLF1-Derived T Cells Show
Similar Intracellular Cytokine Secretion after PMA-Ionomycin
Stimulation in HI-HSCT Recipients
B6SJLF1 B6CBAF1
CD4, % 8.24 ± 1.84 9.92 ± 1.17
CD8, % 11.3 ± 2.8 13.3 ± 2.7
Biol Blood Marrow Transplant 18:1808-1818, 2012 1817Double Haploidentical TransplantHI-HSCT resulted in early neutrophil and platelet re-
covery after transplantation. Interestingly, early HI
engraftment shifted to the durable engraftment of
UCB at day 180 posttransplantation, suggesting that
stem cell function is critical for long-term engraft-
ment.Murinemodels have demonstrated better prolif-
erative potential of UCB cells compared with adult
BM-derived stem cells [29], which might affect
engraftment kinetics posttransplantation. In the pres-
ent study, we have shown that the engraftment poten-
tial of stem cells can affect long-term chimerism, and,
unlike in double UCB transplantation studies, both
BM cells continue to show mixed chimerism even
3 months after transplantation. In addition, cell dose,
order of infusion, and compatibility of MHC mole-
cules do not apply in our transplantationmodels, given
the infusion of the same number of cells through the
same tail vein injection procedure.
In conclusion, TCD-BM cells engraft well in
recipients of DH-HSCT, without the risk of GVG
and GVHD. Dominant T cells play a role in early
engraftment of stem cells but might not be critical in
long-term engraftment, specifically in TCD models.
We believe that HI-HSCT has a potential to enhance
the GVT effect after transplantation, which warrants
further clinical trials in patients at high risk for relapse
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